Search
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedIn general, the drug was well tolerated by patients during cardiac examinations [A32091]. … One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.
Categories: Compounds used in a research, industrial, or household settingAtacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy. … [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
Amifostine
go.drugbank.com/drugs/DB01143ApprovedInvestigationalA phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Categories: Compounds used in a research, industrial, or household settingProducts: Ethyol - Pws IV 500mg/vialDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Synonyms: N-Hydroxyacetamide, N-AcetylhydroxylamineProducts: CIPROFLOXACINO 200MG/20MLCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset
Resorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalIt is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses
Mixtures: Good Neighbor Pharmacy VagicaineAlbutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016. … It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]
Danaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnThe use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. … Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT).
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]